(Q85158783)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Matthew G Fury

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Sofia Haque

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Hilda Stambuk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ronglai Shen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Diane Carlson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

David Pfister

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

4 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

795-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Preclinical and clinical studies with combinations of pemetrexed and gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25464

7 January 2021

Identifiers

DOI

10.1002/CNCR.25464

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922785%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference